INNSBRUCK, Austria, June 03, 2025--Bruker Corporation (NASDAQ: BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed.

In other recent news, Bruker Corporation reported its first-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.47, compared to a forecast of $0.42.

Bruker today is run by CEO Frank Laukien, the son of the founder Gunther Laukien. In aggregate, the Laukien family owns over 30% of the outstanding shares.

Bruker Spatial Biology will be at booth #2320 at the AACR General Meeting and will share more details on these innovations in their spotlight theater on Tuesday, April 29 at 3:00PM CT titled ...

Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring Provided by Business Wire Apr 16, 2025, 3:00:00 AM ...

Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR Unique Fourier 80 ‘Multi-Talent’ offers 1H NMR and choice of 15 X-nuclei with just one click At the Joint ENC-ISMAR ...

Bruker Spatial Biology also plans to announce the extension of their collaboration with Weill Cornell Medicine on the Spatial Atlas of Human Anatomy (SAHA) initiative, to create multicellular ...

Frank Laukien, President and CEO, reported that Bruker achieved Q4 2024 constant exchange rate (CER) revenue growth of 15.8%, with reported revenues reaching $979.6 million and organic growth of 3.9%.

Bruker (NASDAQ: BRKR) Corporation reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of $0.76 against the forecast of $0.74. Revenue also ...

Bruker is down 15.6% during the same time and is heading into earnings with an average analyst price target of $73.19 (compared to the current share price of $51.72).

Bruker Spatial is part of the BSI Nano segment, for which Bruker reported revenues of $492.9 million for the first half of this year, up 13% from $434.7 million in Q1–Q2 2023.

Bruker put forward the winning bid for NanoString’s portfolio this past April, outdoing Patient Square Capital’s offer by paying about $392.6 million through a Chapter 11 auction.